Onyia Jude, Chief Scientific Officer at Neurocrine Biosciences (NBIX), has demonstrated a clear selling bias in recent years, with $13.5 million in total sales outweighing $6.8 million in purchases across 35 transactions. The activity is concentrated entirely in NBIX, with no trades in other companies. The most significant disposals occurred in mid-2025, including a $7.8 million sale on July 9 and a $2.6 million sale on July 2, both accompanied by option exercises (codes S and M). More recently, Jude's transactions have shifted to smaller, routine dispositions—four sales since January 2026, including a $1.33 million transaction on February 13 and a $342,056 sale in November 2025. The absence of any buys since at least 2025, coupled with the continuation of sales into early 2026, suggests a sustained pattern of reducing exposure to Neurocrine stock. Notably, several filings in February 2026 show $0 value transactions (codes G and A), likely reflecting grants or awards rather than market purchases. The data reveals a disciplined approach to monetizing equity, with no purchases to offset the steady stream of sales over the past year.
AI-assisted summary